AU2019293687B2 - Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy - Google Patents

Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy

Info

Publication number
AU2019293687B2
AU2019293687B2 AU2019293687A AU2019293687A AU2019293687B2 AU 2019293687 B2 AU2019293687 B2 AU 2019293687B2 AU 2019293687 A AU2019293687 A AU 2019293687A AU 2019293687 A AU2019293687 A AU 2019293687A AU 2019293687 B2 AU2019293687 B2 AU 2019293687B2
Authority
AU
Australia
Prior art keywords
week
treatment
viltolarsen
pharmaceutical composition
dystrophin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019293687A
Other languages
English (en)
Other versions
AU2019293687A1 (en
Inventor
Youichi EGAWA
Takashi Natsukawa
Youhei Satou
Tomonori UNO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AU2019293687A1 publication Critical patent/AU2019293687A1/en
Application granted granted Critical
Publication of AU2019293687B2 publication Critical patent/AU2019293687B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2019293687A 2018-06-26 2019-06-26 Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy Active AU2019293687B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690270P 2018-06-26 2018-06-26
US62/690,270 2018-06-26
US201862739386P 2018-10-01 2018-10-01
US62/739,386 2018-10-01
PCT/JP2019/026393 WO2020004675A1 (ja) 2018-06-26 2019-06-26 アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025283628 Division 2019-06-26

Publications (2)

Publication Number Publication Date
AU2019293687A1 AU2019293687A1 (en) 2021-01-07
AU2019293687B2 true AU2019293687B2 (en) 2025-10-02

Family

ID=68987235

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019293687A Active AU2019293687B2 (en) 2018-06-26 2019-06-26 Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy

Country Status (20)

Country Link
US (2) US20210261963A1 (enExample)
EP (1) EP3815696A4 (enExample)
JP (3) JP7345466B2 (enExample)
KR (1) KR20210023988A (enExample)
CN (1) CN112399849A (enExample)
AU (1) AU2019293687B2 (enExample)
BR (1) BR112020026542A2 (enExample)
CA (1) CA3101321A1 (enExample)
CL (1) CL2020003367A1 (enExample)
CO (1) CO2020015685A2 (enExample)
EC (1) ECSP20083454A (enExample)
IL (1) IL279692A (enExample)
MX (2) MX2020013880A (enExample)
MY (1) MY209148A (enExample)
PE (1) PE20210630A1 (enExample)
PH (1) PH12020552078A1 (enExample)
SG (1) SG11202011554PA (enExample)
TW (1) TW202035692A (enExample)
WO (1) WO2020004675A1 (enExample)
ZA (1) ZA202007682B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
IL307937A (en) 2021-04-30 2023-12-01 Sarepta Therapeutics Inc Treatment methods for muscular dystrophy
US20250195667A1 (en) 2022-03-17 2025-06-19 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
CN121194802A (zh) * 2023-02-14 2025-12-23 斯托克制药公司 反义寡聚物调配物
TW202448485A (zh) * 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612917A1 (en) * 2010-09-01 2013-07-10 Nippon Shinyaku Co., Ltd. Antisense nucleic acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009033A1 (en) 1989-12-20 1991-06-27 Anti-Gene Development Group Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
CA2942791C (en) 2002-11-25 2019-08-20 Masafumi Matsuo Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
USRE47769E1 (en) 2004-06-28 2019-12-17 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
HRP20140646T1 (hr) 2007-11-15 2014-09-26 Sarepta Therapeutics, Inc. Postupak sinteze morfolino oligomera
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
TR201902952T4 (tr) 2008-10-24 2019-03-21 Sarepta Therapeutics Inc Dmd için ekson atlama bileşimleri.
CN111893117B (zh) * 2012-01-27 2024-06-04 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
SMT201900139T1 (it) * 2013-03-14 2019-05-10 Sarepta Therapeutics Inc Composizioni di salto dell'esone per il trattamento della distrofia muscolare
MX373959B (es) 2013-03-15 2020-07-13 Sarepta Therapeutics Inc Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
EP3015467B1 (en) * 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
WO2017059131A1 (en) * 2015-09-30 2017-04-06 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
FR3044926B1 (fr) * 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2612917A1 (en) * 2010-09-01 2013-07-10 Nippon Shinyaku Co., Ltd. Antisense nucleic acid

Also Published As

Publication number Publication date
JP7595719B2 (ja) 2024-12-06
BR112020026542A2 (pt) 2021-04-06
US20210261963A1 (en) 2021-08-26
MX2020013880A (es) 2021-03-09
JPWO2020004675A1 (ja) 2021-07-15
WO2020004675A1 (ja) 2020-01-02
EP3815696A4 (en) 2022-11-30
US20240158792A1 (en) 2024-05-16
CN112399849A (zh) 2021-02-23
CO2020015685A2 (es) 2021-04-30
JP2025028961A (ja) 2025-03-05
ZA202007682B (en) 2024-04-24
ECSP20083454A (es) 2021-01-29
CA3101321A1 (en) 2020-01-02
JP7345466B2 (ja) 2023-09-15
MY209148A (en) 2025-06-24
IL279692A (en) 2021-03-01
PH12020552078A1 (en) 2021-05-31
TW202035692A (zh) 2020-10-01
AU2019293687A1 (en) 2021-01-07
EP3815696A1 (en) 2021-05-05
SG11202011554PA (en) 2020-12-30
JP2023171731A (ja) 2023-12-05
MX2025001486A (es) 2025-03-07
CL2020003367A1 (es) 2021-05-24
KR20210023988A (ko) 2021-03-04
PE20210630A1 (es) 2021-03-23

Similar Documents

Publication Publication Date Title
AU2019293687B2 (en) Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy
TWI713450B (zh) 藉由使用反義寡核苷酸創造提前終止密碼子抑制或下調肝醣合成酶
WO2024035946A1 (en) Oligonucleotide compositions and methods thereof
JP2018530560A (ja) デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
US11939577B2 (en) Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease
US20220251551A1 (en) Exon skipping oligomers for muscular dystrophy
TW201919655A (zh) 治療肌肉萎縮症的方法
US20240011029A1 (en) Modified oligonucleotides for use in treatment of tauopathies
WO2025030155A1 (en) Oligonucleotide compositions and methods thereof
CN114729355A (zh) Ppm1a抑制剂以及使用其的方法
US20250179487A1 (en) Exon skipping oligomer conjugates for muscular dystrophy
US20240327831A1 (en) Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
HK40049503A (en) Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
RU2799442C2 (ru) Композиция, содержащая антисмысловой олигонуклеотид, и ее применение для лечения мышечной дистрофии дюшенна
US20240344067A1 (en) Exon skipping oligomers for muscular dystrophy
TW202406557A (zh) 治療杜興氏肌肉失養症之方法
WO2024187097A2 (en) Compositions and methods for modulating sptlc1
WO2026006477A1 (en) Oligonucleotide compositions and methods thereof
JP2024535445A (ja) オフターゲット効果を回避するための方法及び組成物